Drug Database
Back to search

Poland· PL-100463270

Remsima

A infliximab product containing infliximabum, registered in Poland by Celltrion Healthcare Hungary Kft.. The same ATC class is registered in 14 of our 19 countries.

ATC L04AB02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedRemsimaATCL04AB02REGISTER NO.PL-100463270PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about infliximabumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Infliximab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AB02 (infliximab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search infliximab products by name

Infliximab · ATC L04AB02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of infliximab costs, country by country.

Normalised to the WHO defined daily dose (3.75 mg), the median price runs from $0.31 in Finland to $24.45 in Switzerland — a ×79 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Infliximab · price per daily dose (3.75 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$24.45
  • FI Finland$0.31
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Infliximabum
Manufacturer
Celltrion Healthcare Hungary Kft.
Country
Poland (PL)
ATC code
L04AB02
ATC class
Infliximab
Defined daily dose
3.75 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

443 interactions on record for infliximab.

Graded by severity as the source publishes them — 290 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check infliximab against other medicinesHow interaction checks work

Infliximab · interactions on record

443 records

  • 290 severe
  • 146 moderate
  • 7 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Infliximab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All infliximab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Remicade, Remsima
  • Liechtenstein · Remicade, Remsima
  • Norway · Remicade, Remsima

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/acb6e31d-a0b5-4d36-8e9e-de81a258deb6
GET /v1/drugs/acb6e31d-a0b5-4d36-8e9e-de81a258deb6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
  "source": "urpl",
  "strength": "120 mg",
  "packaging": "Rpz ¦ EU/1/13/853/006 ¦ 143323\n1 amp.-strzyk. 1 ml\nRpz ¦ EU/1/13/853/010 ¦ 143324\n2 amp.-strzyk. 1 ml\nRpz ¦ EU/1/13/853/008 ¦ 143325\n4 amp.-strzyk. 1 ml\nRpz ¦ EU/1/13/853/009 ¦ 143326\n1 amp.-strzyk. 1 ml\nRpz ¦ EU/1/13/853/007 ¦ 143327\n2 amp.-strzyk. 1 ml\nRpz ¦ EU/1/13/853/011 ¦ 143328\n4 amp.-strzyk. 1 ml\nRpz ¦ EU/1/13/853/015 ¦ 143338\n6 amp.-strzyk. 1 ml\nRpz ¦ EU/1/13/853/016 ¦ 143339\n6 amp.-strzyk. 1 ml",
  "substance": "Infliximabum 120 mg",
  "common_name": "Infliximabum",
  "pl_product_id": "100463270",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about infliximab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console